Clinical trial
PSMA Response in Metastasized Hormone Sensitive Prostate Cancer - Enzalutamide
NCT05539300 · UMC Utrecht, Other · Unknown status
Key facts
| NCT number | NCT05539300 |
|---|---|
| Title | PSMA Response in Metastasized Hormone Sensitive Prostate Cancer - Enzalutamide |
| Official title | Individualisation of Management With Novel Upfront Therapies in Newly Diagnosed Metastasized Prostate Cancer Using (PSMA)PET/CT Imaging - Enzalutamide |
| Acronym | PET-MaN-enza |
| Lead sponsor | UMC Utrecht, Other |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Diagnostic Test |
| Interventions | PSMA-PET/CT response evaluation |
| Enrollment | 150 |
| Start date | Mar 1, 2023 |
| Primary completion | Jan 1, 2026 |
| Completion | Jan 1, 2026 |
| First posted | Sep 14, 2022 |
| Last update posted | Jan 9, 2024 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: